US009636427B2

(12) **United States Patent**
Meyer et al.

(10) **Patent No.: US 9,636,427 B2**
(45) **Date of Patent: May 2, 2017**

(54) **PROCESS FOR PREPARING A PHARMACEUTICAL FORMULATION OF CONTRAST AGENTS**

(71) Applicant: **GUERBET**, Villepinte (FR)

(72) Inventors: **Dominique Meyer**, La Rochelle (FR); **Claire Corot**, Lyons (FR); **Marc Port**, Deuil la Barre (FR); **Vincent Barbotin**, Montmorency (FR); **Bruno Bonnemain**, Villeparisis (FR)

(73) Assignee: **GUERBET**, Villepinte (FR)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **15/140,077**

(22) Filed: **Apr. 27, 2016**

(65) **Prior Publication Data**

US 2016/0235867 A1 Aug. 18, 2016

Related U.S. Application Data

(63) Continuation of application No. 12/918,259, filed as application No. PCT/EP2009/051937 on Feb. 18, 2009, which is a continuation of application No. 12/155,997, filed on Jun. 12, 2008, now abandoned.

(30) **Foreign Application Priority Data**

Feb. 19, 2008 (FR) 08 51055
Apr. 17, 2008 (EP) 08154745

(51) **Int. Cl.**
A61K 49/10 (2006.01)
A61K 45/06 (2006.01)
A61K 9/00 (2006.01)

(52) **U.S. Cl.**
CPC ***A61K 49/108*** (2013.01); ***A61K 9/0019*** (2013.01); ***A61K 45/06*** (2013.01); ***A61K 49/106*** (2013.01)

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,639,365	A	1/1987	Sherry
4,647,447	A	3/1987	Gries et al.
4,877,600	A	10/1989	Bonnemain et al.
5,049,667	A	9/1991	Schaefer et al.
5,082,649	A	1/1992	VanDeripe
5,098,692	A	3/1992	Gries et al.
5,362,475	A	11/1994	Gries et al.
5,364,613	A	11/1994	Sieving et al.
5,650,133	A	7/1997	Carvalho et al.
5,846,517	A	12/1998	Unger
5,876,695	A	3/1999	Gries et al.
5,958,373	A	9/1999	Garrity et al.
7,385,041	B2	6/2008	Chang et al.
2003/0059368	A1	3/2003	Groman et al.
2004/0170566	A1	9/2004	Chang et al.

FOREIGN PATENT DOCUMENTS

EP	0 270 483 A2	6/1988
EP	0 481 526 A1	4/1992
EP	0 454 078 B1	10/1996
FR	2 590 484 A1	5/1987
JP	4-504436 A	2/1992
JP	4-504436 A	8/1992
JP	2005-534697 A	11/2005
WO	WO 86/02352 A1	4/1986

(Continued)

OTHER PUBLICATIONS

"A Guideline on Summary of Product Characteristics (SmPC)", Revision 2, Sep. 2009.
"Excipients in the label and package leaflet of medicinal products for human use", vol. 3B, Guidelines: Medicinal products for human use safety, environment and information, Jul. 2003.
"MRI Contrast Agent", Pharmacia, vol. 37, No. 5, 2001, pp. 420-421 with English language translation.
"Nephrogenic Systemic Fibrosis: an Uncommon and Debilitating Disease Possibly Associated with Gadolinium Chelates", Guerbet Contrast for Life, Information for Healthcare Professionals and Investors, (online), Dec. 21, 2007, pp. 1-7, XP002499276.
"Nephrogenic Systemic Fibrosis: An uncommon and Debilitating Disease Possibly Associated with Gadolinum Chelates", Information for Healthcare Professionals and other Stakeholders, dated Jul. 2, 2008.
"Stability of linear and macrocyclic gadolinium based contrast agents", The British Journal of Radiology, vol. 80, pp. 581-585, 2007.

(Continued)

Primary Examiner — Nissa Westerberg
(74) *Attorney, Agent, or Firm* — Birch, Stewart, Kolasch & Birch, LLP

(57) **ABSTRACT**

The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.25%, the macrocyclic chelate advantageously being chosen from DOTA, NOTA, DOTAGA, DO3A, BT-DO3A, HP-DO3A and PCTA, and is preferably DOTA, the said process comprising the following successive steps: b) preparation of a liquid pharmaceutical composition containing, firstly, the complex of macrocyclic chelate with a lanthanide, and, secondly, free macrocyclic chelate and/or free lanthanide; c) measurement in the pharmaceutical formulation obtained in step b) of the concentration of free macrocyclic chelate C_{ch1} and/or of free lanthanide C_{lan1}; d) adjustment of C_{ch1} and/or of C_{lan1} so as to obtain $C_{ch1}=C_{t\,ch1}$ and $C_{lan1}=0$, wherein $C_{t\,ch1}$ is the target concentration of free macrocyclic chelate in the final liquid pharmaceutical formulation.

20 Claims, No Drawings